ImmuneLongevity

Thymalin

Polypeptide · Thymic extract fraction · Bovine-derived

FDA · NOT REVIEWED (RUSSIAN RESEARCH)

Half-life

~2.5 hours

Short

minsdays

Route

SubQ injection

Evidence

Early human data

Risk

Standard

Overview

Known for

Thymic peptide extract. Restores immune function, particularly in aging individuals. Regulates T-cell maturation and function. Less studied than Thymosin Alpha-1 but with decades of clinical use in Russia.

Mechanism

Extract of bovine thymus — mixture of thymic peptides. Similar intent to Thymosin Alpha-1 but less purified/standardized. 30+ years Russian clinical use.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Authoritative
Supply & nature
Natural / Topping UpNatural
FDA category
Not reviewed (Russian research)

Evidence & standing

Evidence base
Early human data
Risk level
Standard
Best studies
5 references
  • Khavinson & Morozov (2003) — Russian geroprotector studies
  • Limited English-language peer-reviewed data
  • Primarily Russian/CIS clinical research
  • NOT FDA APPROVED
  • Based on thymic extract — less characterized than Thymosin Alpha-1

Dosage & protocol

Typical dose
5-10mg
Research range
5–20 mg
Cycle
10-day course / 3–6 months off
Onset
7 days first effects
Full effect
60 days
Half-life
~2-3h
~2-3 hours (estimated)
Protocol

5-10mg daily IM or SubQ for 5-10 day courses. Repeated 1-2x per year.

Time to effects

EARLY: During course

FULL: 1-3 months post-course

5-10 day course: Immune modulation initiated.

1-3 months after course: Full immunomodulatory effects realised. The short course is designed to 'reset' thymic function.

Benefits are measured in immune markers and illness frequency over the following months, not in immediate subjective feelings. Repeat courses 1-2x per year.

Recommended vial
  • 10mg (only size)

At 10mg/day for 5-10 day courses = 1 vial per day. Used immediately. No shelf life issue.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Fully Reversible
Side effects

Injection site reaction, allergic reaction possible (bovine-derived), flu-like symptoms. Limited Western safety data.

Interactions

Immunosuppressives (may counteract)

Handle with research caution

  • Same immunosuppressant caution as Thymosin Alpha-1

Storage & handling

Lyophilised
12–24 months
room temp
Reconstituted
1–2 weeks
2–8°C